Romaco, supplier of processing and packaging equipment, has acquired STE Tecpharm, S. L., a Spanish manufacturer of processing technology.
Romaco, supplier of processing and packaging equipment, has acquired STE Tecpharm, S. L., a Spanish manufacturer of processing technology. The acquisition was announced in a March 18, 2021 press release.
Following the transaction, Tecpharm, which employs approximately 30 people at its site near Barcelona, Spain, will operate as an independent business unit of Romaco Group. The acquisition is expected to strengthen Romaco’s position as a turnkey supplier of processing technologies.
“With the takeover of Tecpharm and its patented high-tech tablet coating machines, we can decisively expand our portfolio,” said Jörg Pieper, CEO, Romaco Group, in the press release. “Tecpharm manufactures drum coaters that embody economic efficiency, reliability, and batch flexibility—and therefore perfectly fits the products and quality standards of Innojet and Kilian. This new constellation creates valuable synergistic effects, which we intend to leverage systematically in order to offer our customers state-of-the-art processing solutions.”
“I regard the exit to Romaco as a milestone in our relatively young company history,” added David Mateo, managing director of Tecpharm, S. L., in the press release. “Our integration into such a successful global player will create major growth opportunities for Tecpharm. The support we get from Romaco’s worldwide sales and service network will allow us to expand the reach of these products enormously and boost our sales accordingly. Moreover, Romaco is a very decentralised organization, which will ease our integration with our new sister companies at eye level.”
Source: Romaco
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.